GNW-News: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson

Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson

Actelion Pharmaceuticals Ltd /

Actelion announces changes to its executive team upon completion of the

transaction with Johnson & Johnson

. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.

Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

Source: Globenewswire

ALLSCHWIL/BASEL, SWITZERLAND - 15 May 2017 - Actelion Ltd (SIX: ATLN) today

announced changes to its executive team that would only take effect upon closing

of the transaction with Johnson & Johnson expected towards the end of the second

quarter 2017.

Johnson & Johnson has appointed Jane Griffiths as the Global Head of Actelion,

to take effect upon closing of the transaction.

Dr. Griffiths, PhD has served as the Company Group Chairman, Janssen EMEA, since

January 2011. Prior to leading Janssen EMEA, she was responsible for the EMEA

Market Access unit. She has also served as International Vice President for

Janssen-Cilag Northern Europe; Vice President, EMEA Biopharmaceuticals; and

Managing Director, Ortho Biotech UK & Ireland.

Otto Schwarz, PhD, will retire from his position as Chief Operating Officer,

upon close of the transaction. He will work closely with Jane Griffiths as

senior advisor for the 12 months following the completion of the transaction on

the smooth integration of Actelion into Janssen/Johnson & Johnson  and the

seamless execution of Actelion's commercial strategies to maintain the strong

momentum.

Jean-Paul Clozel, MD, Chief Executive Officer, commented: "I would like to thank

Otto for his very significant contributions to the success of Actelion in the

almost 9 years since he joined the company. Under his leadership Tracleer was

built into a global brand with almost 1.7 billion Swiss francs in peak sales. He

also led and managed the highly successful launches of Opsumit, Uptravi and

Veletri, thus replacing the leading drug in the category with a diversified,

outcome-based portfolio, which has a strong long-term growth potential to

achieve leading positions in shaping the treatment paradigms in PAH, an

achievement which is a rare feat  in our industry."

###

NOTES TO EDITORS

Actelion Ltd.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,

development and commercialization of innovative drugs for diseases with

significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our

portfolio of PAH treatments covers the spectrum of disease, from WHO Functional

Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Although not available in all countries, Actelion has treatments approved by

health authorities for a number of specialist diseases including Type 1 Gaucher

disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from

systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell

lymphoma.

Founded in late 1997, with now over 2,600 dedicated professionals covering all

key markets around the world including the US, Japan, China, Russia and Mexico,

Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN). All

trademarks are legally protected.

For further information please contact:

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

www.actelion.com

The above information contains certain "forward-looking statements", relating

to the company's business, which can be identified by the use of forward-looking

terminology such as "estimates",  "believes", "expects", "may", "are expected

to", "will", "will continue", "should", "would be", "seeks",  "pending" or

"anticipates" or similar expressions, or by discussions of strategy, plans or

intentions.  Such statements include descriptions of the company's investment

and research and development programs and anticipated expenditures in connection

therewith, descriptions of new products expected to be introduced by the company

and anticipated customer demand for such products and products in the company's

existing portfolio. Such statements reflect the current views of the company

with respect to future events and are subject to certain risks, uncertainties

and assumptions. Many factors could cause the actual results, performance or

achievements of the company to be materially different from any future results,

performances or achievements that may be expressed or implied by such forward-

looking statements. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual results

may vary materially from those described herein as anticipated, believed,

estimated or expected.

Medienmitteilung PDF:

http://hugin.info/131801/R/2104828/798821.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Actelion Pharmaceuticals Ltd via GlobeNewswire

http://www.actelion.com